Tacrolimus ointment in the management of atopic dermatitis

References

• Schultz-LarsenFDiepgenTSvensonnAThe occurrence of atopic dermatitis in north Europe: an international questionnaire studyJ Am Acad Dermatol1996347607648632070
   PubMed Web of Science ®Google Scholar
• KayJGawkrodgerDJMortimerMJJaronAGThe prevalence of childhood atopic eczema in general populationJ Am Acad Dermatol19943035398277028
   PubMed Web of Science ®Google Scholar
• ReitamoSWollenbergASafety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitisArch Dermatol200036999100610926735
   PubMedGoogle Scholar
• LeungDYMAtopic dermatitis: new insights and opportunities for therapeutic interventionJ Allergy Clin Immunol200010586087610808164
   PubMed Web of Science ®Google Scholar
• BohmeMSvenssonAKullINordvallSLClinical features of atopic dermatitis at two years of ageActa Derm Venereol20018119319711558876
   PubMed Web of Science ®Google Scholar
• HanifinJMRajkaGDiagnostic features of atopic eczemaActa Derm Venereol1980Suppl 924447
   Google Scholar
• AkdisCAkdisMBieberTDiagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/Practall Consensus ReportAllergy20066196998716867052
   PubMed Web of Science ®Google Scholar
• BernardLAEichfieldLFTopical immunomodulators for atopic dermatitisCurr Opinion Pediatr20021441441812130904
   PubMed Web of Science ®Google Scholar
• DoldSWjstMvon MutiusEGenetic risk for asthma, allergic rhinitis, and atopic dermatitisArch Dis Child199267101810221520004
   PubMed Web of Science ®Google Scholar
• CorkMJRobinsonDAVasilopoulosYNew perspectives in epidermal barrier dysfunction in atopic dermatitis: Gene-environment interactionsJ Allergy Clin Immunol200611832116815133
   PubMed Web of Science ®Google Scholar
• OngPYLeungDYImmune dysregulation in atopic dermatitisCurr Allergy Asthma Rep20066538438916899200
   PubMed Web of Science ®Google Scholar
• HenninoAVocansonMBerardFEpidemiology and pathophysiology of eczemasRev Prat200615:56324925716583949
   PubMedGoogle Scholar
• BosJDMeinardiMMThe 500 Dalton rule for the skin penetration of chemical compounds and drugsExp Dermatol2000916516910839713
   PubMed Web of Science ®Google Scholar
• VickeryBPSkin barrier function in atopic dermatitisCurr Opin Pediatr200719899317224668
   PubMed Web of Science ®Google Scholar
• WütrichBSchmid-GrendelmeierPBieberTLeungDYMDefinition and diagnosis of intrinsic versus extrinsic atopic dermatitisAtopic dermatitis1st edNew YorkMarcel Dekker Inc2002120
   Google Scholar
• HoareCLi Wan PoAWilliamsHSystematic review of treatments of atopic dermatitisHealth Technol Assess2000437119111134919
   PubMedGoogle Scholar
• WahlgrenCFItch and atopic dermatitis: an overviewJ Dermatol1999261177077910635621
   PubMedGoogle Scholar
• AbererWWolffKBieberTLeungDYMSystemic PharmacotherapyAtopic dermatitisMarcel Dekker IncNew York, Basel2002595602
   Google Scholar
• YajimaYSuekiHOguroTYoshidaTIijimaMEffects of oral administration of ciclosporin A on skin carcinogenesis: a study using the two-stage carcinogenesis protocol in miceClin Exp Dermatol200833447848318498406
   PubMed Web of Science ®Google Scholar
• SchmittJSchäkelKSchmittNSystemic treatment of severe atopic dermatitis: A systematic reviewActa Derm Venereol20078710011117340015
   PubMed Web of Science ®Google Scholar
• SmithJGWehrRFChalkerDKCorticosteroid induced cutaneous atrophy and teleangiectasiaArch Dermatol197611211151117952530
   PubMed Web of Science ®Google Scholar
• KrutmannJTMoritaABieberTLeungDYMPhototherapy for atopic dermatitisAtopic dermatitisMarcel Dekker IncNew York, Basel2002501551
   Google Scholar
• NordwigSTThomasALThe treatment of atopic dermatitis with topical immunomodulatorsClin Dermatol20032121522412781439
   PubMed Web of Science ®Google Scholar
• RustinMHAThe safety of tacrolimus ointment for the treatment of atopic dermatitis: a reviewBr J Dermatol200715786187317854353
   PubMed Web of Science ®Google Scholar
• NghiemPPearsonGLangleyRGTacrolimus and pimecrolimus: for cleaver prokaryotes to inhibiting calcineurin and treating atopic dermatitisJ Am Acad Dermatol20024622824111807435
   PubMed Web of Science ®Google Scholar
• KinoTHatanakaHMiglyataSFK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effest of FK-506 in vitroJ Antibiot198740125612652445722
   PubMed Web of Science ®Google Scholar
• LiuJAlbersMWWandlessTJInhibition of T-cell signalling by immunophilin-ligand complexes correlates with loss of calcineurin phosphatase activityBiochemistry199231389639011373650
   PubMed Web of Science ®Google Scholar
• BanerjiSSParsonsJNTocciMJThe immunosuppressant FK-506 specifically inhibits mitogen-induced activation of the interleukin-2 promoter and the isolated enhancer elements NFIL-2A and NF-AT1Mol Cell Biol199111407440871712901
   PubMed Web of Science ®Google Scholar
• TocciMJMatkovichDACollierKAThe immunosuppressant FK506 selectively inhibits expression of early T-cell activation genesJ Immunol19891437182762472451
   PubMed Web of Science ®Google Scholar
• KappAAllenBRReitamoSAtopic dermatitis management with tacrolimus ointment (Protopic)J Dermatolog Treat200314 Suppl51614522634
   PubMedGoogle Scholar
• FleischerABJrTreatment of atopic dermatitis: role of tacrolimus ointment as a topical noncorticosteroidal therapyJ Allergy Clin Immunol1999104126130
   Web of Science ®Google Scholar
• KayeREFrumanDABiererBEEffects of cyclosporine A and FK506 on Fc epsilon receptor type I-initiated increases in cytokine mRNA in mouse bone marrowderived progenitor mast cells: resistance to FK506 is associated with a deficiency in FK506-binding protein FKBP12Proc Natl Acad Sci U S A199289854285461382293
   PubMed Web of Science ®Google Scholar
• WollenbergASharmaSvon BubnoffDTopical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitisJ Allergy Clin Immunol200110751952511240954
   PubMed Web of Science ®Google Scholar
• TrautmannAAkdisMSchmid-GrendelmeierPTargeting keratinocyte apoptosis in the treatment of atopic dermatitis and allergic contact dermatitisJ Allergy Clin Immunol2001108583984611692113
   PubMed Web of Science ®Google Scholar
• NeckermannGBavandiAMeingassnerJGAtopic dermatitis-like symptoms in hypomagnesaemic hairless rats are prevented and inhibited by systemic or topical SDZ ASM 981Br J Dermatol200014266967910792216
   PubMed Web of Science ®Google Scholar
• SengokuTMoritaKSakumaSPossible inhibitory mechanism of FK506 (tacrolimus hydrate) ointment for atopic dermatitis based on animal modelsEur J Pharmacol199937918318910497905
   PubMed Web of Science ®Google Scholar
• MeingassnerJGdi PadovaFHiestandPPimecrolimus (Elidel, SDZ ASM 981) in contrast to cyclosporin A and tacrolimus, is highly effective in animal models of skin inflammation but has only low activity in models indicating immunosuppressive potentialPediatr Dermatol200118 Suppl76
   Google Scholar
• ReitamoSVan LeentEJMHoVEfficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitisJ Allergy Clin Immunol200210953954611898004
   PubMed Web of Science ®Google Scholar
• ReitamoSRemitzAKyllönenHTopical noncorticosteroid immunomodulation in the treatment of atopic dermatitisAm J Clin Dermatol2002338138812113647
   PubMedGoogle Scholar
• ReitamoSRustinMRuzickaTEfficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitisJ Allergy Clin Immunol200210954755511898005
   PubMed Web of Science ®Google Scholar
• ReitamoSHarperJBosJD0.03% tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate-to-severe atopic dermatitis: results of a randomized double-blind controlled trialBr J Dermatol200415055456215030341
   PubMed Web of Science ®Google Scholar
• PacorMLDi LorenzoGMartinelliNComparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: a randomized studyClin Exp Allergy20043463964515080819
   PubMed Web of Science ®Google Scholar
• KangSLuckyAWPariserDLong-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in childrenJ Am Acad Dermatol200144 Suppl 5864
   Google Scholar
• HanifinJMPallerASEichenfieldLUS Tacrolimus Ointment Study GroupEfficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitisJ Am Acad Dermatol200553 Suppl186194
   Web of Science ®Google Scholar
• RemitzAHarperJRustinMEuropean Tacrolimus Ointment Study GroupLong term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in childrenActa Derm Venereol200787546117225017
   PubMed Web of Science ®Google Scholar
• ReitamoSOrtonneJPSandCCambazardFEuropean Tacrolimus Ointment Study GroupA multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate-to-severe atopic dermatitisBr J Dermatol20051521282128915948994
   PubMed Web of Science ®Google Scholar
• PallerAEichenfieldLFLeungDYA 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patientsJ Am Acad Dermatol200144 Suppl4757
   Web of Science ®Google Scholar
• SoterNAFleischerABWebsterGFTacrolimus Ointment Study GroupTacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part II. SafetyJ Am Acad Dermatol2001443946
   Web of Science ®Google Scholar
• KangSLuckyAWPariserDLong-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in childrenJ Am Acad Dermatol200144 Suppl5864
   Web of Science ®Google Scholar
• BaldoACasulaLPrizioETopical tacrolimus and vitiligo: our experience in sixty casesG Ital Dermatol Venereol2007142621625
   Google Scholar
• ArellanoFMWentworthCEAranaARisk for lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitisJ Invest Dermatol200712780881617096020
   PubMed Web of Science ®Google Scholar
• FleisherABLingMEichenfieldLTacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infectionsJ Am Acad Dermatol200247456257012271302
   PubMed Web of Science ®Google Scholar
• CallenJChamlinSEichenfieldLFA systematic review of the safety of topical therapies for atopic dermatitisBr J Dermatol200715620322117223859
   PubMed Web of Science ®Google Scholar
• HarperJSmithCRubinsAA multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitisJ Invest Dermatol2005124469569915816825
   PubMed Web of Science ®Google Scholar
• FujisawaSummary of product characteristicsProtopic tacrolimus 0.003% and 0.1% ointment42002
   Google Scholar
• BreuerKWerfelTKappASafety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitisAm J Clin Dermatol20056657715799678
   PubMed Web of Science ®Google Scholar
• LawrenceALamersonCSheehanPMTacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric patients: results from a randomized, double-blind, vehicle-controlled studyPediatrics20051163334342
   Web of Science ®Google Scholar
• ReitamoSRissanenJRemitzATacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trialJ Invest Dermatol19981113963989740230
   PubMed Web of Science ®Google Scholar
• AlaitiSKangSFiedlerVCTacrolimus (FK506) ointment for atopic dermatitis: a phase I study in adults and childrenJ Am Acad Dermatol19983869769448208
   PubMed Web of Science ®Google Scholar
• PournarasCCLubbeJSauratJHStaphylococcal colonization in atopic dermatitis treatment with topical tacrolimus (FK506)J Invest Dermatol200111648048111231333
   PubMed Web of Science ®Google Scholar
• RemitzAKyllonenHGranlundHTacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesionsJ Allergy Clin Immunol200110719619711150013
   PubMed Web of Science ®Google Scholar
• ReitamoSEuropean Tacrolimus Ointment Study Group0.1% Tacrolimus ointment is significantly more efficacious than a steroid regimen in adults with moderate to severe atopic dermatitis12th Congress of the European Accademy of Dermatology and VenereologySt Julian’s, Malta27 February – 1 march Poster presentation128
   Google Scholar
• NaylorMElmetsCARicoMJTreatment with topical tacrolimus is not associated with an increase in non-melanoma skin cancersThe American Academy of Dermatology 60th Annual MeetingNew Orleans, LA, USA22–27 February 2002 Poster presentation18
   Google Scholar
• Astellas Pharma GmbHSummaries of Product CharacteristicsProtopic 003% OintmentMununich, GermanyAstellas Pharma GmbH2006
   Google Scholar
• BaldoAPrizioEMansuetoGA case of chronic actinic dermatitis treated with topical tacrolimusJ Dermatolog Treat20051624524816249148
   PubMed Web of Science ®Google Scholar